Wednesday, June 10, 2026

Patent intelligence · US

US 2020131224

Methods for Synthesis of Radionuclide Complex

granted A61K 51/ 04 A IA61K 51/ 08 A IA61K 51/ 12 A IA61K/510482
Status granted
Pipeline programs 6
Years to expiry 14
Applicant portfolio 25
Patent details — US 2020131224
Jurisdiction
US
Status
granted
Grant date
Apr 30, 2020
Expiration
Apr 25, 2040
CPC classes
A61K 51/ 04 A I, A61K 51/ 08 A I, A61K 51/ 12 A I, A61K/510482
View on Google Patents ↗

Quick answer

US 2020131224 (Methods for Synthesis of Radionuclide Complex) is held by ADVANCED ACCELERATOR APPLICATIONS ITALY S R L [IT]. Status: granted. Granted Apr 30, 2020. Expires Apr 25, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 51/ 04 A I, A61K 51/ 08 A I, A61K 51/ 12 A I, A61K/510482, A61K/51083, A61K/51088

More from ADVANCED ACCELERATOR APPLICATIONS ITALY S R L [IT]

Related pharmaceutical patents in our USPTO index.

  1. EP 4541380

    STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN

    ADVANCED ACCELERATOR APPLICATIONS S A [FR] · Expires Apr 18, 2045

    granted
  2. CA 3235923

    PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES

    ADVANCED ACCELERATOR APPLICATIONS [FR] · Expires Aug 5, 2043

    granted
  3. CA 3240096

    POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON

    NOVARTIS AG [CH] · Expires May 14, 2043

    granted
  4. CA 3234495

    POLYTHERAPIE DE COMPLEXE DE RADIONUCLEIDES

    NOVARTIS AG [CH] · Expires Apr 29, 2043

    granted
  5. CA 3215723

    PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE

    ADVANCED ACCELERATOR APPLICATIONS [FR] · Expires Oct 1, 2042

    granted
  6. CA 3202908

    ANTAGONISTE D'INTEGRINES ALPHA-V BETA-3 ET/OU ALPHA-V BETA-5 RADIOMARQUE DESTINE A ETRE UTILISE EN TANT QU'AGENT THERAGNOSTIQUE

    ADVANCED ACCELERATOR APPLICATIONS INT SA [CH] · Expires Jun 25, 2042

    granted
  7. US 2022072166

    METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS

    ADVANCED ACCELERATOR APPLICATIONS S A [FR] · Expires Mar 5, 2042

    granted
  8. WO 2022043557

    MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA

    ADVANCED ACCELERATOR APPLICATIONS INT SA [CH] · Expires Feb 26, 2042

    granted

Frequently asked questions

What is US patent 2020131224?

US 2020131224 (Methods for Synthesis of Radionuclide Complex) is held by ADVANCED ACCELERATOR APPLICATIONS ITALY S R L [IT]. Status: granted. Granted Apr 30, 2020. Expires Apr 25, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 2020131224?

ADVANCED ACCELERATOR APPLICATIONS ITALY S R L [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does US 2020131224 expire?

Our index shows an expiration date of Apr 25, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.